Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 9/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 6/20 | 0.37 |
| ▸ | NPY1R | P25929 | 4/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047760 | 0.93 | FURIN (0.41) | FURINHTTNPY4RNPY1RNPY2R | |
| SCHEMBL29339858 | 0.90 | FURIN (0.43) | FURINHTTNPY4RNPY1RNPY2R | |
| SCHEMBL24864481 | 0.88 | FURIN (0.43) | FURINHTTSMN1; SMN2 | |
| SCHEMBL29342071 | 0.87 | FURIN (0.43) | FURIN | |
| SCHEMBL24864480 | 0.87 | NPY4R (0.42) | FURINHTTNPY4RNPY1RNPY2R | |
| SCHEMBL24864665 | 0.86 | NPY4R (0.44) | FURINNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31558978 | 0.86 | FURIN (0.41) | FURINHTTNPY4RNPY1RNPY2R | |
| SCHEMBL31559049 | 0.85 | CA2 (0.43) | FURIN | |
| SCHEMBL29345954 | 0.85 | FURIN (0.44) | FURINHTTSMN1; SMN2 | |
| SCHEMBL24297455 | 0.85 | FURIN (0.43) | FURINHTTNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | FURIN 1498/4885HTT 2334/4885NPY4R 1409/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | FURIN 398/4885HTT 2664/4885NPY4R 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.